<SEC-DOCUMENT>0001140361-19-010923.txt : 20190612
<SEC-HEADER>0001140361-19-010923.hdr.sgml : 20190612
<ACCEPTANCE-DATETIME>20190612172534
ACCESSION NUMBER:		0001140361-19-010923
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190610
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190612
DATE AS OF CHANGE:		20190612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		19894343

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 6.0.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM 8-K</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CURRENT REPORT</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Date of report (Date of earliest event reported):&#160; June 10, 2019</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(Exact Name of Registrant as Specified in Charter)</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Delaware</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(State or Other Jurisdiction of Incorporation)</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z61888a71c5814286984f96b2e59e4a4f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">000-19125</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">33-0336973</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(Commission File No.)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(IRS Employer Identification No.)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2855 Gazelle Court</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Carlsbad, CA 92010</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(Address of Principal Executive Offices and Zip Code)</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Registrant&#8217;s telephone number, including area code: <font style="font-weight: bold;">(760) 931-9200</font></div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>
    <div><font style="font-family: 'Times New Roman', Times, serif;"> </font><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="za5f58ba25fbe408dbf93652b788e2083" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#9744;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-indent: -36pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;"> </font><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z0ffed515ab6c4931a04e68105ed530b9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#9744;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-indent: -36pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;"> </font><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z53ed45944a97434281d200add390e29b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#9744;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-indent: -36pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;"> </font><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z194de3ba1ccb4c9a8426c3de24c3db65" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#9744;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Securities registered pursuant to Section 12(b) of the Act:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z99479ef8d3e24c3c9cf239cf19b2e8ae" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Title of each class</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Trading symbol</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Name of each exchange on which registered</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Common Stock, $.001 Par Value</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;IONS&#8221;</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">The Nasdaq Stock Market, LLC</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule
      12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z11bc41cce6ed4839a359df7bb14ec5f1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">Emerging growth company</div>
          </td>
          <td style="width: 10%; vertical-align: top; text-align: right;">&#9744;</td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z347216383f794ac78bcb94956b8c9672">

          <tr>
            <td style="width: 99%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
              Section 13(a) of the Exchange Act.&#160; </td>
            <td style="width: 1%; text-align: right; vertical-align: bottom;">&#9744;</td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="z6b95ed77f34747f69fba2cb9557dd4a4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 5.02</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zbf4b45c16ac34ed1b89850f47aca3fba" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;">Appointment of Joan Herman to Board of Directors</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="font-family: 'Times New Roman', Times, serif;">On June 10, 2019, the Board of Directors (the &#8220;<font style="font-weight: bold; font-style: italic;">Board</font>&#8221;) of Ionis Pharmaceuticals, Inc. (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;) appointed Joan Herman, President and Chief Executive Officer of Herman and Associates LLC, as a member of the Company&#8217;s Board, effective immediately.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">There are no arrangements or understandings between Ms. Herman and any other persons pursuant to which Ms. Herman was appointed as a director of the Company.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Ms. Herman will receive the standard director compensation that the Company provides to its non-employee directors of $55,000 per calendar year and will be eligible for automatic equity grants
      under the Company&#8217;s Amended and Restated 2002 Non-Employee Directors&#8217; Stock Option Plan.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">In addition, Ms. Herman will enter into the Company&#8217;s standard form of indemnity agreement.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">A copy of the press release announcing the appointment of Ms. Herman is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</div>
    <div><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zfd9ed0269a5a4189aef5d16b325f8765" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 9.01</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Financial Statements and Exhibits.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z44ab715919574e3abdfa856ec6a668d2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">(d)</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Exhibits</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="ze5191b47942c4fbe89a2930887822dc1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 27pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;"><a href="ex99_1.htm">99.1</a></td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Press Release dated June 12, 2019.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-variant: small-caps; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by
      the undersigned, thereunto duly authorized.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z7a810d479dc74c11ac209a9e4025f598" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-variant: small-caps; font-weight: bold;">Ionis Pharmaceuticals, Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Dated:&#160; June 12, 2019</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">/s/ Patrick R. O&#8217;Neil</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Senior Vice President, Legal, General </div>
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Counsel and Chief Compliance Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
  </div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 6.0.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div><br>
    <div><img width="202" height="67" src="image0.jpg"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Ionis announces appointment of Joan E. Herman to its board of directors</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">Carlsbad, Calif., June 12, 2019</font> &#8211; Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of
      a new member to its board of directors effective immediately &#8211; Joan E. Herman, MBA, MS, president and chief executive officer of Herman and Associates, LLC. With the appointment of Ms. Herman, the Ionis board of directors increases to 12 members.</div>
    <div><font style="font-family: 'Times New Roman', Times, serif;"> </font><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">&#8220;We are pleased to welcome Joan Herman to the Ionis board. She joins Ionis at an exciting time as we celebrate our 30-year anniversary with three commercial medicines and an industry-leading
      pipeline of more than 40 medicines, many with blockbuster potential,&#8221; said Stanley T. Crooke, M.D, Ph.D., Ionis founder, chief executive officer, and chairman of the board. &#8220;Joan&#8217;s distinguished career in the healthcare industry, along with her
      extensive experience in business operations and development make her an outstanding addition to our board.&#8221;</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Ms. Herman is currently president and CEO of Herman &amp; Associates, a management consulting firm that specializes in advising private equity firms investing in healthcare. She has deep
      experience leading healthcare and payor companies, serving in several executive positions at Anthem (formerly WellPoint), including as president and CEO of the Consumer Business unit, president and CEO of the Specialty, Senior and State Sponsored
      Business and group president, Senior and Specialty Businesses. Ms. Herman also served as a senior vice president of Phoenix Life Insurance Company. Ms. Herman currently serves on the board of directors for Encompass Health (formerly HealthSouth) and
      previously served on the boards of both Convergys and AARP Services, Inc. She has earned degrees from Barnard College, Columbia University (summa cum laude, BS Mathematics), Yale University (MS) and Western New England University (MBA).</div>
    <div><br>
    </div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ABOUT IONIS PHARMACEUTICALS, INC.</div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery
        platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet
        needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin
        amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases,
        pulmonary diseases and cancer.</font></div>
  </div>
  <div>
    <div style="font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF; color: #000000;">&#160;&#160;&#160; <br>
      </font></div>
    <div style="font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF; color: #000000;">To learn more about Ionis follow us on twitter @ionispharma or visit </font><font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif;"><u>www.ionispharma.com</u></font><font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif;">.</font></div>
  </div>
  <div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="background-color: #FFFFFF;">&#160;&#160;&#160; <br>
      </font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="background-color: #FFFFFF;">Ionis Pharmaceuticals Investor Contact:</font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">D. Wade Walke, Ph.D.</font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">Vice President, Investor Relations</font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">760-603-2741</font></div>
  </div>
  <div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="background-color: #FFFFFF;">&#160;&#160;&#160; <br>
      </font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="background-color: #FFFFFF;">Ionis Pharmaceuticals Media Contact:</font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">Roslyn Patterson</font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">Vice President, Corporate Communications</font></div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">760-603-2681</font></div>
  </div>
  <div><br>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ": = # 2(  A$! Q$!_\0
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MW_OQ_P#7H_X7'X4_OWO_ 'X_^O7SU177[&)]7_8V&\_O/H7_ (7'X4_OWO\
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M1Y1X7\</^1ETW_KS_P#9VKRZO4?CA_R,NF_]>?\ [.U>75VT_A1]IEW^ZP]
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M5Z?\&=!O[G79-;2=H+&U#1.H)_TAF7[GI@9#'/?;QW'#^&O#]UXGUVWTRU#
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M>BYM4&%@NU\Q5&   <A@  , ''M6$Z/6)X.+R;FDYT';R_R/IBBO&+?XZSK
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M/:RO+_:OVM1>ZMO/_@'OG@_XL:9K:K:ZP8M.O\X#%L0R\9R&/W3P>&/I@DG
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M %_1?^A"G+8NO_"EZ,^J*R/$VOP^&?#]UJTT,DRP@;8T_B8G"@G^$9(Y_F<
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M[*#UVKVSZDX&<5G4GRKS/.S'&+#TFD_>>W^9T]%%%<9\>?'5%?6'_",Z!_T
M]-_\!(_\*/\ A&= _P"@'IO_ ("1_P"%=?M/(^N_M'^[^/\ P#Y/KU3X&_\
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MVFY .UA@Y1>B\C(/+#/WC78T45DVWN>35JSJRYIN["BBBD9A1110!X7\</\
MD9=-_P"O/_V=J\NKZYO-)TW4)%DO=/M+EU&U6FA5R!Z9(JM_PC.@?] /3?\
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1MMZL\2<Y3ES2=V%%%%(D_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
